Telemonitoring to Treat Group 2 Pulmonary Hypertension
Status:
Not yet recruiting
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This study aims to decrease elevated pressure in the lungs of patients with pulmonary
hypertension from left heart with elevated pulmonary vascular resistance by utilizing
aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with
persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in
combination with the fluid management plan while those with improved pressures maintain their
fluid management plan for an additional 16 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Mardi Gomberg -Maitland
Collaborators:
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) Ohio State University